The Akribion Genomics team has received the Hessischer Gründerpreis (Hessian Founder Award) and was also recognized as the winner in its category. The team received the award in the category “Innovative Business Idea” for the discovery and development of an alternative CRISPR-Cas nuclease, which the start-up company intends to develop into a new class of genetically based cancer therapies.
The Supervisory Board, the Management Board of BRAIN Biotech AG has resolved, to issue convertible bonds in the total nominal amount of EUR 5.0 million, making partial use of the authorization of the ordinary annual general meeting on 8 March 2023.
BRAIN Biotech Group will merge AnalytiCon Discovery GmbH into BRAIN Biotech AG in order to further optimize and simplify the group structure.
BRAIN Biotech reports a significant milestone payment of € 1.5 million for the successful development progress in the out-licensed active pharmaceutical ingredient program with deucrictibant.
BRAIN Biotech presents MetXtra™, a comprehensive technology platform that enables innovative solutions for industrial biocatalysis.
BRAIN Biotech concluded a royalty monetization deal on the royalty rights to an investigational compound, deucrictibant, with Royalty Pharma for up to EUR 128.88 million.
